Conduit Pharmaceuticals reports advancements in lupus studies and trial designs. The Company partnered with Charles River ...

Today, the Lupus Foundation of America announced a new, groundbreaking collaborative lupus clinical trial program – LFA Lupus ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimm ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Autoimmune diseases make the immune system attack healthy tissues. These can affect organs like kidneys, leading to ...

In this, my body cells are attacking the organ, so in my case, it’s sometimes Lupus; it hits your kidneys or causes arthritis ... who has been vocal about her struggle with myositis — an autoimmune ...

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the treatment of lupus nephritis. Obinutuzumab is a monoclonal ...